In last trading session, Bicycle Therapeutics Plc ADR (NASDAQ:BCYC) saw 0.27 million shares changing hands with its beta currently measuring 0.90. Company’s recent per share price level of $24.58 trading at -$0.11 or -0.45% at ring of the bell on the day assigns it a market valuation of $1.04B. That closing price of BCYC’s stock is at a discount of -17.62% from its 52-week high price of $28.91 and is indicating a premium of 48.98% from its 52-week low price of $12.54. Taking a look at company’s average trading volume volume of 399.79K if we extend that period to 3-months.
Bicycle Therapeutics Plc ADR (NASDAQ:BCYC) trade information
Upright in the red during last session for losing -0.45%, in the last five days BCYC remained trading in the green while hitting it’s week-highest on Thursday, 05/02/24 when the stock touched $24.58 price level, adding 8.15% to its value on the day. Bicycle Therapeutics Plc ADR’s shares saw a change of 35.95% in year-to-date performance and have moved 8.14% in past 5-day. Bicycle Therapeutics Plc ADR (NASDAQ:BCYC) showed a performance of 8.71% in past 30-days.
Bicycle Therapeutics Plc ADR (BCYC) estimates and forecasts
Statistics highlight that Bicycle Therapeutics Plc ADR is scoring comparatively lower than the scores of other players of the relevant industry. The company added 60.13% of value to its shares in past 6 months, showing an annual growth rate of -2.36% while that of industry is 12.80. Apart from that, the company came lowering its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 31.20% from the last financial year’s standing.
10 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 5.72M for the same. And 10 analysts are in estimates of company making revenue of 5.73M in the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -12.36% during past 5 years.
BCYC Dividends
Bicycle Therapeutics Plc ADR is more likely to be releasing its next quarterly report in June and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
